Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
The effects of N2-(N-acetyl-muramyl-L-alanyl-D-isoglutamyl)-N6-stearoyl-L-lysine (MDP-Lys(L18], a muramyl dipeptide (MDP) analog, on the immune responses in mice were studied. MDP-Lys(L18) augmented the mitogenic responses of splenic lymphocytes to phytohemagglutinin (PHA) and lipopolysaccharide (LPS) at 0.1-10 micrograms/ml, and antibody formation to sheep red blood cell (SRBC) in normal and immunosuppressed mice, and to dinitrophenyl (DNP)-Ficoll. In addition, MDP-Lys(L18) potentiated polyclonal B cell activation both in vivo and in vitro. It was also found that MDP-Lys(L18) augmented the cellular immune responses, such as mixed lymphocyte reaction (MLR) and delayed type hypersensitivity (DTH). These effects of MDP-Lys(L18) were more potent than those of MDP. These findings may be attributed to the interleukin 1 (IL-1)-inducing activity of MDP-Lys(L18).
Akasaki
M
M
Research Institute, Daiichi Seiyaku Co. Ltd., Tokyo, Japan.
Takashi
T
T
Kita
Y
Y
Tsukada
W
W
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D002999:Clone Cells / Q000276:immunology; D005260:Female; D006462:Hemolytic Plaque Technique; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007375:Interleukin-1 / Q000378:metabolism; D037102:Lectins / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008934:Mitogens / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D007375:Interleukin-1; D037102:Lectins; D008934:Mitogens; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C036866:romurtide